Arrowhead Pharmaceuticals IncARWR
Price$65.45

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $669.5M+18,753.7% YoYTTM through 30 Jun 2026
Net Income -$320MTTM through 30 Jun 2026
Free Cash Flow -$75.1MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-30.2%
Operating Margin-191.6%
Net Margin-47.8%

Returns

-68.7%ROE
-15.1%ROA

Balance Sheet Health

Debt / Equity2.13x
Current Ratio5.90x
Net Debt$627.9M
Cash & Equivalents$54.8M

Quality Metrics

Altman Z-Score3.18
Piotroski F-Score3 / 9
FCF Margin-11.2%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $829.4M
Diluted EPS-$2.28TTM
'19'20'21'22'23'24'25
FY2025: $-0.01

Dividend

No dividend

Capital Allocation

Capex Intensity2.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.